Search | VHL Regional Portal

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Gavin, Patrick J; Suseno, Mira T; Thomson, Richard B; Gaydos, J Michael; Pierson, Carl L; Halstead, Diane C; Aslanzadeh, Jaber; Brecher, Stephen; Rotstein, Coleman; Brossette, Stephen E; Peterson, Lance R.

Antimicrob Agents Chemother ; 50(6): 2244-7, 2006 Jun.

Article in English | MEDLINE | ID: mdl-16723596

ABSTRACT

We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility.

Subject(s)

Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Klebsiella oxytoca/drug effects , Klebsiella pneumoniae/drug effects , beta-Lactamase Inhibitors , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Escherichia coli/enzymology , Escherichia coli/isolation & purification , Female , Humans , Klebsiella oxytoca/enzymology , Klebsiella oxytoca/isolation & purification , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/isolation & purification , Male , Microbial Sensitivity Tests , Middle Aged , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/pharmacology , Penicillanic Acid/therapeutic use , Piperacillin/pharmacology , Piperacillin/therapeutic use , Piperacillin, Tazobactam Drug Combination , Retrospective Studies , Time Factors , Treatment Outcome , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL